Search - tctmd.com

Displaying 241 - 260 of 261

Sort: Relevancy | Date

News Conference News

EVOLVE: Bioabsorbable EES Noninferior to Permanent Polymer Version

November 10, 2011

News Conference News

SPIRIT PRIME: EES Efficacy ‘Similar and Consistent’ with Xience V Technology

November 08, 2011

News Conference News

Low Event Rates with EES Sustained at 2 Years

November 08, 2011

News Conference News

EES Compared Favorably with SES In Two Pivotal Trials

November 08, 2011

News Conference News

APICE-OCT: EES, ZES Yield Low Rates of Uncovered Struts in ACS

November 08, 2011

News Conference News

ZES, EES Noninferior to PES

November 07, 2011

News Conference News

EES Associated with Reduced MACE Compared with SES

November 07, 2011

News Conference News

Early Discontinuation of DAPT May Increase Risk of Stent Thrombosis

November 06, 2011

News Daily News

Xience Shows Noninferior Late Loss to Cypher, Similar Hard Outcomes

October 17, 2011

News Daily News

Meta-analysis: Everolimus-Eluting Stents Reduce Thrombosis vs. Other DES

September 14, 2011

News Conference News

ESC Congress 2011: Drugs, Devices Work Together

Caitlin E. Cox

September 06, 2011

News Conference News

Two Trials Show Favorable Results with XIENCE V vs. Earlier DES, BMS

September 02, 2011

News Conference News

RESET: Largest Study to Date of Xience, Cypher Shows Noninferiority

August 31, 2011

News Daily News

No Apparent Advantage for Everolimus vs. Paclitaxel Stents in Diabetic Patients

L.A. McKeown

August 19, 2011

News Daily News

ESSENCE-DIABETES Published: Xience, Cypher Equally Equipped to Treat Diabetics

Caitlin E. Cox

August 03, 2011

News Daily News

Meta-analysis Finds Equivalence Between First-, Second-Generation DES

L.A. McKeown

August 02, 2011

News Daily News

RESOLUTE All Comers Looks at Simple, Complex Cases in Comparing ZES, EES

L.A. McKeown

June 10, 2011

News Daily News

EES Show Long-term Safety Advantage over SES

L.A. McKeown

May 24, 2011

News Daily News

Everolimus-Eluting Stents Found Equivalent to First-Generation Stents in Most Patients at 1 Year

Leah Lawrence

April 26, 2011

News Daily News

Two-Year Data Published from SPIRIT IV, COMPARE: Xience Still Favored Over Taxus

April 20, 2011

Advertisement

EVOLVE: Bioabsorbable EES Noninferior to Permanent Polymer Version

SPIRIT PRIME: EES Efficacy ‘Similar and Consistent’ with Xience V Technology

Low Event Rates with EES Sustained at 2 Years

EES Compared Favorably with SES In Two Pivotal Trials

APICE-OCT: EES, ZES Yield Low Rates of Uncovered Struts in ACS

ZES, EES Noninferior to PES

EES Associated with Reduced MACE Compared with SES

Early Discontinuation of DAPT May Increase Risk of Stent Thrombosis

Xience Shows Noninferior Late Loss to Cypher, Similar Hard Outcomes

Meta-analysis: Everolimus-Eluting Stents Reduce Thrombosis vs. Other DES

ESC Congress 2011: Drugs, Devices Work Together

Two Trials Show Favorable Results with XIENCE V vs. Earlier DES, BMS

RESET: Largest Study to Date of Xience, Cypher Shows Noninferiority

No Apparent Advantage for Everolimus vs. Paclitaxel Stents in Diabetic Patients

ESSENCE-DIABETES Published: Xience, Cypher Equally Equipped to Treat Diabetics

Meta-analysis Finds Equivalence Between First-, Second-Generation DES

RESOLUTE All Comers Looks at Simple, Complex Cases in Comparing ZES, EES

EES Show Long-term Safety Advantage over SES

Everolimus-Eluting Stents Found Equivalent to First-Generation Stents in Most Patients at 1 Year

Two-Year Data Published from SPIRIT IV, COMPARE: Xience Still Favored Over Taxus

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content